#USA #Denver #ASN Kidney Week #Kibow Therapeutics #KT-301

Kibow Therapeutics Presents Phase 2b Results for KT-301

Introduction
In an exciting development for the nephrology community, Kibow Therapeutics, a biotech leader focused on microbiome-based therapies, will present ground-breaking results at the ASN Kidney Week 2026. Scheduled from October 21 to 25 in the vibrant city of Denver, Colorado, this event marks a pivotal moment for ongoing research in chronic kidney disease (CKD).

Phase 2b Study Overview
Kibow Therapeutics will unveil the results of its Phase 2b clinical trial involving KT-301, a novel therapeutic targeting Stage 4 CKD. The randomized, double-blind study engaged 327 patients, aiming to explore the efficacy of modulating the gut microbiome through a specialized synbiotic treatment. This approach could hold the key to slowing kidney disease progression, an area critically underserved by traditional therapies.

Chief Medical Officer Dr. Robert Segal will lead the presentation, explicitly focusing on how KT-301 could potentially provide relief to patients battling the advanced stages of kidney disease. "For those with Stage 4 CKD, options remain limited in addressing the disease's progression rather than merely its symptoms," Dr. Segal stated.

Mechanistic Research Findings
In addition to the clinical trial data, Kibow will present a separate laboratory study detailing the mechanisms of action behind KT-301. Led by Dr. Usha Vyas, the investigation delves deeper into the interactions between specific probiotics and the gut microbiome, utilizing advanced lab models to simulate human intestinal conditions. Understanding these mechanisms promises to offer invaluable insights into how KT-301 can effectively influence gut health in CKD patients.

Commitment to Research Excellence
Kibow Therapeutics, founded in 1997, has dedicated nearly three decades to exploring the intricate relationship between intestinal health and kidney function. This commitment has fostered a better understanding of how gut bacteria influence the metabolism of waste compounds and immune responses, ultimately affecting kidney health. The company's participation at ASN Kidney Week reaffirms its dedication to advancing kidney care through scientific discovery and cross-disciplinary collaboration.

The ASN Kidney Week serves as a global gathering, bringing together experts, researchers, and healthcare leaders passionate about enhancing patient care and preventing kidney disease. This year's theme reflects the latest innovations in diagnostics and management strategies, making it an ideal platform for Kibow's significant revelations.

Upcoming Presentations
The following presentations are scheduled for October 23:

• - Oral Presentation by Dr. Robert Segal:

- Title: CKD-Strain Specific Probiotic KT-301 Significantly Slows Progression in Stage 4 CKD
- Time: 5:00 – 5:10 PM MDT

• - Poster Presentation by Dr. Usha Vyas:

- Title: Effect of CKD-Specific Probiotic Strain KT-301 on Uremic Toxin-Induced Dysbiosis Using Human Intestinal Microbial Ecosystem Simulator (SHIME) Reactor Technology
- Time: 10:00 AM – 12:00 PM MDT

Conclusion
As Kibow Therapeutics continues to push boundaries in CKD treatment, the insights from these studies could revolutionize our understanding and management of this complex disease. With ongoing research and development of microbiome-based therapies, Kibow is poised to transform the lives of patients living with kidney disease, a significant unmet need in the healthcare landscape.

For further details and to stay updated on their work, visit the Kibow Therapeutics website at www.kibowtx.com.